Holen Sie sich die Stockscreener-App
7.4934
2.60%
-0.1866
Schlusskurs vom Vortag:
$7.68
Offen:
$7.4
24-Stunden-Volumen:
738.64K
Relative Volume:
0.94
Marktkapitalisierung:
$557.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-13.38
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
-1.45%
1M Leistung:
+4.03%
6M Leistung:
+106.63%
1J Leistung:
-17.07%
1-Tages-Spanne:
$7.33
$7.66
1-Wochen-Bereich:
$7.33
$8.44
52-Wochen-Spanne:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
7.48 | 572.27M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.76 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.28 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.93 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
838.08 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.91 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikesTake Profit & Risk Controlled Stock Pick Alerts - newser.com
How to build a dashboard for Corvus Pharmaceuticals Inc. stockExit Point & Fast Gaining Stock Strategy Reports - newser.com
Corvus to present final data on T cell lymphoma drug at ASH meeting - Investing.com
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to present soquelitinib 1/1b T‑cell lymphoma data at ASH - Stock Titan
Corvus Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Real time social sentiment graph for Corvus Pharmaceuticals Inc.2025 Performance Recap & Entry Point Strategy Guides - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackRate Hike & Safe Capital Growth Trade Ideas - newser.com
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com
Why Corvus Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming base2025 Big Picture & Verified Entry Point Signals - newser.com
What momentum indicators show for Corvus Pharmaceuticals Inc. stockJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.Quarterly Earnings Report & Fast Exit and Entry Trade Guides - newser.com
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth - Sahm
Corvus Pharmaceuticals Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Tuesday - MarketBeat
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Corvus Pharmaceuticals, Inc. (CRVS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Corvus Pharmaceuticals, Inc. (CRVS) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Corvus Pharmaceuticals Inc. stock momentum explained2025 Analyst Calls & Precise Buy Zone Tips - newser.com
ETFs Investing in Corvus Pharmaceuticals, Inc. Stocks - TradingView
Will Corvus Pharmaceuticals Inc. stock benefit from green energy trendsEarnings Risk Report & Growth Focused Entry Reports - Fundação Cultural do Pará
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to host Nov. 4 webcast for financial results update - Stock Titan
How Corvus Pharmaceuticals Inc. stock reacts to Fed rate cuts - fcp.pa.gov.br
Will Corvus Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & AI Based Trade Execution Alerts - fcp.pa.gov.br
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.Analyst Downgrade & Safe Swing Trade Setup Alerts - newser.com
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):